In ONWARDS 5 study, once-weekly insulin icodec was found to be non-inferior to once-daily basal insulin in reducing HbA1c. With that, the 52-week open-label trial met its primary endpoint at the end of the study.
Novo’s icodec led to a reduction of -1.68% points on HbA1c, compared to -1.31% for the once-daily control. The study comprised 1,085 insulin-naive people with type 2 diabetes. Patients on icodec also used an app to guide their dosing.
The news adds to ONWARDS trial readouts dating back to April.
In July, the company announced headline results from the ONWARDS 3 and ONWARDS 4 Phase 3a trials with once-weekly insulin icodec.
Earlier this month, Novo picked up worldwide marketing rights to Zealand Pharma A/S’s (NASDAQ: ZEAL) diabetes treatment Zegalogue and inked a $1.1 billion buyout of Forma Therapeutics Holdings Inc (NASDAQ: FMTX) for its sickle cell drug.
Novo Nordisk expects to file for regulatory approval of once-weekly insulin icodec in the U.S., the EU, and China in 1H of 2023.
Price Action: NVO shares are up 2.26% at $101.88 on the last check Monday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.